Buy MBDB (N-methyl-1-3-benzodioxolylbutanamine) Cas 135795-90-3

MBDB, also known as N-methyl-1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine, is an entactogen of the phenethylamine, amphetamine, and phenylisobutylamine families related to MDMA.^{[1][2][3][4][5]} It is known by the nicknames “Eden” and “Methyl-J“.^[5]

MBDB was first synthesized by pharmacologist and medicinal chemist David E. Nichols and later tested by Alexander Shulgin and described in his book, PiHKAL: A Chemical Love Story.^[1] MBDB’s dose, according to PiHKAL, is 180 to 210 mg; the proper dosage relative to body mass seems unknown.^[1][2] Its duration is 4 to 8 hours, with noticeable after-effects lasting for 1 to 3 hours.^[1][2]

MBDB was initially developed as a non-psychedelic entactogen. It has lower effects on the dopamine system in comparison to other entactogens such as MDMA. MBDB causes many mild, MDMA-like effects, in particular the lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, and mild euphoria, all of which are present.^[1] MBDB tends to produce less euphoria, psychedelia, and stimulation in comparison to MDMA.^[1]

Clinical studies have found that MBDB produces similar entactogenic effects to MDMA, but lacks psychedelic and stimulant effects.^[2][3] It enhances mood similarly to MDMA, but lacks the pronounced euphoria of MDMA.^[2] MBDB produces prosocial effects similarly to MDMA, although it is said to be moderately less effective.^[2]

MBDB acts as a serotonin–norepinephrine releasing agent (SNRA).^[2][3][6] Its EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release are 540 nM for serotonin, 3,300 nM for norepinephrine (6.1-fold lower than for serotonin), and >100,000 for dopamine (>185-fold lower than for serotonin).^[6] However, it may still have slight dopamine-releasing actions.^[3] MBDB fully substitutes for MDMA in drug discrimination tests in rodents.^[2][3] It increases locomotor activity similarly to but less robustly than MDMA.^[7] Likewise, MBDB increases conditioned place preference (CPP) similarly but less efficaciously than MDMA.^[3] In contrast to MDMA, which produced hyperthermia, MBDB instead produced dose- and time-dependent hypothermia